Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:1377:171-187.
doi: 10.1007/978-981-19-1592-5_14.

HDL and Therapy

Ke Li  1 , Xianwei Xie  2 , Yansong Guo  3   4   5   6   7
Affiliations

HDL and Therapy

Ke Li et al. Adv Exp Med Biol. 2022.

Abstract

A wealth of evidence indicates that high-density lipoprotein assumes the unique antiatherosclerosis and other cardioprotective properties. Based on that, HDL-C has been considered as a promising therapy target to reduce the cardiovascular diseases. Recombinant HDL (rHDL) and apolipoprotein mimetic peptides emerge in recent years and have great potential in the future. Here we discussed the pleiotropic therapeutic effect of rHDL based on the effects of atherogenic, angiogenesis, platelet, vascular, and Alzheimer's disease. On the other hand, rHDL not only plays the key role as the major protein component of HDL, it is also used as a nanovector in antiatherosclerotic, antitumor, cardiovascular diagnosing and other therapeutic areas. Synthetic apolipoprotein mimetic peptides like apoA-I and and apoE mimetics have undergone clinical assessment, and we have also reviewed the advances of clinical trials and gave an outlook for the therapy of rHDL and mimetic peptides.

Keywords: Apolipoprotein A-I; High-density lipoprotein; Mimetic peptides; Recombinant HDL therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Briel M, Ferreira-Gonzalez I, You JJ et al (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92 - PubMed - PMC - DOI
    1. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58(3):342–374 - PubMed - DOI
    1. Darabi M, Guillas-Baudouin I, Le Goff W et al (2016) Therapeutic applications of reconstituted HDL: when structure meets function. Pharmacol Ther 157:28–42 - PubMed - DOI
    1. Wu BJ, Chen K, Shrestha S et al (2013) High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3beta-hydroxysteroid-Delta24 reductase expression and inducing heme oxygenase-1. Circ Res 112(2):278–288 - PubMed - DOI
    1. Chenevard R, Hurlimann D, Spieker L et al (2012) Reconstituted HDL in acute coronary syndromes. Cardiovasc Ther 30(2):e51–e57 - PubMed - DOI

MeSH terms

LinkOut - more resources